Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial Meeting Abstract
| Authors: | Sharman, J. P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Hallek, M. J.; Coiffier, B.; O'Brien, S. M.; Tausch, E.; Kreuzer, K. A.; Jiang, W.; Jahn, T. M.; Lazarov, M.; Stilgenbauer, S. |
| Abstract Title: | Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203829 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.7011 |
| Notes: | Meeting Abstract: 7011^ -- Source: Wos |
